AlphaStocks
5.3
Consider Buy

Vertex Pharmaceuticals Inc / MA (VRTX)

As of Sep 20, 2026, Vertex Pharmaceuticals Inc / MA (VRTX) scores 5.3/10 on AlphaStocks' five-model composite, #99 of 168 Health Care stocks. At $508, VRTX trades 50% above its model fair value of $339.

Health Care / Biotechnology

S&P 500

$508.29

Below average on several measures. Research carefully.

Consider Buy

Score based on 3 of 5 models — moderate confidence

Data as of Sep 20, 2026

#99out of 168 in Health Care

Is VERTEX PHARMACEUTICALS INC / MA a Good Investment in 2026?

VERTEX PHARMACEUTICALS INC / MA (VRTX) scores 5.3 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates VERTEX PHARMACEUTICALS INC / MA as Attractive (5/9). However, the Graham model rates it Caution — Significantly above fair value. VERTEX PHARMACEUTICALS INC / MA currently trades 50% above its estimated fair value of $339. VERTEX PHARMACEUTICALS INC / MA ranks #99 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

Market Cap129B

Estimated Fair Value

$339.4250% above

Trading above estimated fair value — the market may be pricing in future growth.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

5/9

Buffett

Attractive

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Limited Data

Growth rate vs price (PEG)

Greenblatt

Limited Data

Earnings yield + return on capital

Frequently Asked Questions

Is VERTEX PHARMACEUTICALS INC / MA (VRTX) a good investment?
As of Sep 20, 2026, Vertex Pharmaceuticals Inc / MA (VRTX) scores 5.3/10 on AlphaStocks' five-model composite, #99 of 168 Health Care stocks. At $508, VRTX trades 50% above its model fair value of $339. That score is below average, suggesting caution.
What is VERTEX PHARMACEUTICALS INC / MA's Piotroski F-Score?
VERTEX PHARMACEUTICALS INC / MA's Piotroski F-Score status is Attractive. The raw score is 5/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is VRTX overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $339, VRTX appears overvalued. The stock currently trades 50% above its estimated fair value. Trading above estimated fair value — the market may be pricing in future growth.
How does VRTX compare to other Health Care stocks?
VERTEX PHARMACEUTICALS INC / MA ranks #99 out of 168 stocks in the Health Care sector, placing it in the top 59% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about VRTX?
AlphaStocks evaluates VRTX using five proven investment models. Piotroski: Attractive; Buffett: Attractive; Graham: Caution. These models are combined into a single composite score of 5.3/10.

Similar Stocks

ABBVINCYHRMY

Compare VRTX with

ABBV vs VRTXINCY vs VRTXHRMY vs VRTXVAL vs VRTXPARR vs VRTX

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer